| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_351881098565e35e61b3dd5d7e602f70
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5dafa3999e88ca4157a8159f799e3198 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-40 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2004-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_538b2d3b21edba30e69949b22d9d1c74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_07d9abf091d35b87f0ed63f6a9e81994 |
| publicationDate |
2006-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2006002936-A1 |
| titleOfInvention |
Method of modulating platelet activation |
| abstract |
The present invention relates to a method of treating a disease or condition mediated by platelet activation comprising supplying a therapeutically effective amount of an ERP5 inhibitor to a patient in need thereof, so as to reduce the effects of platelet activation in said patient. |
| priorityDate |
2004-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |